Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small
Personalized Medicine For Better Health
-
19, Oct 2020
-
17, Oct 2020
WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Report
-
15, Nov 2016
Predicting cytomegalovirus viremia after liver or intestine transplantation (
-
15, Nov 2016
Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellula
-
11, Sep 2014
PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA